TY - JOUR
T1 - The yin and yang of retinoic acid signaling in kidney diseases
AU - Wei, Qingqing
AU - Dong, Zheng
N1 - Funding Information:
The authors were supported in part by the grants from the Department of Vet erans Affairs (Merit Review Award I01 BX000319) and the NIH (DK058831, DK087843). ZD is a recipient of a Senior Research Career Scientist award from the Department of Veterans Affairs.
Publisher Copyright:
Copyright: © 2020, American Society for Clinical Investigation.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Retinoic acid (RA) signaling is involved in various physiological and pathological conditions, including development, tumorigenesis, inflammation, and tissue damage and repair. In kidneys, the beneficial effect of RA has been reported in multiple disease models, such as glomerulosclerosis, renal fibrosis, and acute kidney injury. In this issue of the JCI, Chen et al. report a pathway activated by RA signaling that is mediated by the retinoic acid receptor responder protein 1 (RARRES1). Specifically, RARRES1, which is proteolytically cleaved to release the extracellular domain, was endocytosed by podocytes to induce apoptosis and glomerular dysfunction kidney disease. These findings unveil the contrasting aspects, a Janus face, of RA signaling that may guide its therapeutic use.
AB - Retinoic acid (RA) signaling is involved in various physiological and pathological conditions, including development, tumorigenesis, inflammation, and tissue damage and repair. In kidneys, the beneficial effect of RA has been reported in multiple disease models, such as glomerulosclerosis, renal fibrosis, and acute kidney injury. In this issue of the JCI, Chen et al. report a pathway activated by RA signaling that is mediated by the retinoic acid receptor responder protein 1 (RARRES1). Specifically, RARRES1, which is proteolytically cleaved to release the extracellular domain, was endocytosed by podocytes to induce apoptosis and glomerular dysfunction kidney disease. These findings unveil the contrasting aspects, a Janus face, of RA signaling that may guide its therapeutic use.
UR - http://www.scopus.com/inward/record.url?scp=85092258861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092258861&partnerID=8YFLogxK
U2 - 10.1172/JCI141712
DO - 10.1172/JCI141712
M3 - Review article
C2 - 32925167
AN - SCOPUS:85092258861
SN - 0021-9738
VL - 130
SP - 5124
EP - 5126
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 10
ER -